← boardnext 2027-06
NMRA
Neumora Therapeutics, Inc.distress 5/10 · elevated risk$1.51-2%today-58% from 52w high
Psychiatry / CNS 3Neurology 1
Lead: Major Depressive Disorder · target Kappa opioid · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$190M
Runway
1.0 yrs
Shares 1y
+14%
Price & events
-27.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-5.3%
1W
-5.9%
1M
-32.1%
3M
-26.5%
6M
-18.1%
1Y
-87.3%
2Y
—
5Y
-91.1%
All
Overview
- Market Cap
- $280.71M
- Enterprise Value
- $186.60M
- Volume
- 33.27K
- 52 Week Range
- $0.92 – $3.59
- Total Shares
- 185.28M
- Float Shares
- 113.85M
- Short %
- 6.23%
- % Held by Insiders
- 23.60%
- % Held by Institutions
- 57.88%
- RVOL
- 0.01x
- Beta
- 2.77
Pipeline stages · 1 programs
NMRA-335140
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | NMRA-335140 | Major Depressive Disorder | — | active not recruiting |
| 2026-05 | Phase 3 | NMRA-335140 | Major Depressive Disorder | 332 | active not recruiting |
| 2026-05 | Phase 3 | NMRA-335140 | Major Depressive Disorder | 332 | active not recruiting |
| 2025-11-19 | Phase 1 | NMRA-323511 | Alzheimer's Disease, Healthy Elderly | 87 | completed |
| 2025-04-09 | Phase 2 | NMRA-335140 80 mg | Major Depressive Episode Associated With Bipolar II Disorder | 18 | completed |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 17
- 2026Guided 40%trial initiationsecondaryPhase 1NMRA-511 · Initiate multiple ascending dose expansion cohort investigating higher doses.SEC 8-K
- Year end 2026Guided 40%conferencedata presentationsecondaryPhase 1M4 franchise · Provide M4 franchise updateSEC 8-K
- second half of 2026Guided 55%readoutPhase 1NMRA-898 · Report data from ongoing Phase 1 study.SEC 8-K
- 3Q 2026Guided 70%readoutPhase 1NMRA-215 · Biomarker data (hsCRP, IC90) readoutSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2Q 2026readoutPhase 2NMRA-511 · MAD extension data readoutSEC 8-K
- 1H 2026trial initiationsecondaryPhase 1NMRA-215 · Initiate Phase 1 trial for NMRA-215SEC 8-K
- mid-2026conferencedata presentationsecondaryComprehensive M4 franchise updateSEC 8-K
- Mid-2026readoutPhase 3Navacaprant · Topline data from KOASTAL-2 and -3 trialsSEC 8-K
- 2026-06-15trial discontinuednavacaprant · Development of navacaprant discontinued following Phase 3 failures.SEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 1NMRA-215 · Initiate Phase 1 clinical studySEC 8-K
- 2H25readoutPhase 1NMRA-511 · Phase 1b data readoutSEC 8-K
- 2H25readoutPhase 2navacaprant · Phase 2 data readoutSEC 8-K
- 2025-10-27trial initiationsecondaryPhase 1NMRA-898 · Initiation of Phase 1 SAD/MAD study of NMRA-898SEC 8-K
- 1H25regulatory submissionFiled (NDA/BLA)NMRA-M4R · IND submission for next M4 modulator compoundSEC 8-K
- Tuesday, January 14 at 8:15am PTconferencedata presentationsecondaryPhase 3navacaprant · Podium presentation at J.P. Morgan Healthcare ConferenceSEC 8-K
- 2024-04-15clinical holdNMRA-266 · Clinical hold placed on NMRA-266SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $6 (+315% upside) · 8 analysts
- 2026-07-13RBC CapitalOutperform
- 2026-06-18MizuhoOutperform
- 2026-06-16NeedhamBuy
- 2026-06-16HC Wainwright & Co.Buy
- 2026-03-31GuggenheimBuy
- 2026-03-31NeedhamBuy
Competitors — Kappa opioid
- none identified
Recent news
- 2026-07-19Neumora Therapeutics (NMRA) AGM 2026 Summary - Quartr
- 2026-07-16Parkinson's Disease Clinical Trial Pipeline Boom as 150+ - GlobeNewswire
- 2026-07-16Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA) - MarketBeat
- 2026-07-13RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk - marketscreener.com
- 2026-07-09Neumora Therapeutics (NMRA) Edges Higher Amid Modest Gains, Holds Near Key Support - Put Flow Alert - dars.gov.et
- 2026-07-08Neumora Therapeutics (NMRA) Stock Slides 3.76% as Biotech Sentiment Remains Fragile - McClellan Summation - dars.gov.et
- 2026-07-07Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy - Yahoo Finance
- 2026-06-29Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.